Skip to main content
Clinical Trials/ITMCTR2000004026
ITMCTR2000004026
Not yet recruiting
Phase 1

To build a precise diagnosis and treatment system for membranous nephropathy based on the correlation between intestinal microecology and TCM tongue diagnosis

onghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
onghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Observational study
Sex
All

Investigators

Sponsor
onghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • 1\. Diagnosed as primary membranous nephropathy by renal biopsy and clinical examination;
  • 2\. Aged 18\-75 years old;
  • 3\. CKD\<\=3 stage (GFR\>30ml/min), 24\-hour urine protein quantitative \>\=1g;

Exclusion Criteria

  • 1\. Rapidly progressive membranous nephropathy (progressive decline in renal function, necrotizing capillary vasculitis and \>50% large crescent formation on renal biopsy);
  • 2\. Membranous nephropathy with IgA nephropathy;
  • 3\. Have received immunosuppressive drugs or cytotoxic drugs for more than 4 weeks in the past 6 months;
  • 4\. Have received glucocorticoids (prednisone or prednisone) at a dose of more than 20 mg/d for more than 4 weeks in the past 6 months;
  • 5\. Combined with life\-threatening complications such as severe infection;
  • 6\. Those with positive HBV serological indicators other than HbsAb and those with abnormal transaminase in continuous liver function tests;
  • 7\. Patients with malignant tumors or patients with malignant tumor history, history of HIV infection, history of mental illness, acute central nervous system disease, severe gastrointestinal disease, and patients who are prohibited from using immunosuppressive agents;
  • 8\. Abnormal glucose metabolism, fasting blood sugar exceeding 6\.2mmol/L;
  • 9\. Pregnant or lactating women;
  • 10\. Undergoing other clinical trial research;

Outcomes

Primary Outcomes

Not specified

Similar Trials